Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Roche has an average analyst recommendation of "Hold" from 10 firms (1 sell, 5 hold, 4 buy) and an average 12‑month price target of $57.00.
• Several analysts have recently upgraded Roche—Zacks, Goldman Sachs and JPMorgan moved ratings higher—while HSBC reaffirmed a buy with a $57 target.
• The stock opened at $48.72, trading below the consensus target and within a 52‑week range of $34.75–$60.85, and a number of small institutions modestly increased their stakes.

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) has received an average recommendation of "Hold" from the ten research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $57.00.

RHHBY has been the subject of several recent analyst reports. Zacks Research raised shares of Roche from a "strong sell" rating to a "hold" rating in a research report on Monday, January 5th. The Goldman Sachs Group raised shares of Roche from a "sell" rating to a "hold" rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. upgraded shares of Roche from an "underweight" rating to a "neutral" rating in a report on Monday, December 8th. HSBC reaffirmed a "buy" rating and issued a $57.00 price target on shares of Roche in a research note on Wednesday, December 10th. Finally, TD Cowen reissued a "hold" rating on shares of Roche in a research report on Tuesday, February 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oakworth Capital Inc. increased its holdings in shares of Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company's stock valued at $86,000 after acquiring an additional 285 shares in the last quarter. Diversified Trust Co raised its position in shares of Roche by 0.5% during the third quarter. Diversified Trust Co now owns 57,881 shares of the company's stock worth $2,363,000 after purchasing an additional 310 shares during the period. Canopy Partners LLC lifted its holdings in shares of Roche by 4.9% in the 3rd quarter. Canopy Partners LLC now owns 7,580 shares of the company's stock worth $317,000 after purchasing an additional 352 shares in the last quarter. Fulton Bank N.A. grew its position in Roche by 4.6% in the 4th quarter. Fulton Bank N.A. now owns 11,659 shares of the company's stock valued at $604,000 after purchasing an additional 508 shares during the period. Finally, Curio Wealth LLC acquired a new stake in Roche in the 3rd quarter valued at $25,000.

Roche Price Performance

Shares of RHHBY stock opened at $48.72 on Friday. Roche has a fifty-two week low of $34.75 and a fifty-two week high of $60.85. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. The stock has a 50 day simple moving average of $55.33 and a two-hundred day simple moving average of $49.48.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.